Applied DNA Sciences Inc. the Company a leader in Polymerase Chain Reaction PCR-based DNA manufacturing today announced the launch of its Linea COVID-19 Selective Genomic Surveillance SGS Mutation Panel the SGS Panel to enhance the utility of limited Next Generation Sequencing NGS resources in the United States to track better the SARS-CoV-2 Variants of Concern VOCs at local state and federal levels. The SGS Panel uses a matrix of proprietary quantitative polymerase chain reaction qPCR assays that target salient mutations that characterize relevant identified VOCs to narrow the selection of positive samples worth subjecting to NGS analysis which is the only method of conclusively identifying a specific variant. The Company is targeting SGS Panel sales at state and federal government laboratories hospitals academic institutions and certified diagnostic laboratories.Applied DNA is leveraging existing sales channels to market the SGS Panel and recently launched a national ad campaign in Clinical Laboratory News and Genetic Engineering Biotechnology News to support its marketing initiatives. Use of the SGS Panel is currently limited to research use only RUO and is not meant to be diagnostic. The Company will be offering for sale both the SGS Panel RUO in 100 reaction kits and the Companys EUA-authorized Linea COVID-19 Assay Kit the Assay Kit that can detect certain variants via S-gene dropout. The Company believes the combination of the SGS Panel and Assay Kit forms a robust decision matrix to empower the efficient use of NGS resources. The Company is also planning to offer additional RUO services that include NGS sequencing of entire viral genomes. The Company is targeting the sequencing of 100 SARS-CoV-2 viromes per day with a capacity for twice that number.Tracking and containing variant spread is especially important as the population builds national immunity via the vaccine rollout. In addition understanding variant impact on those vaccinated or previously infected by SARS-CoV-2 is essential to the design of variant vaccine boosters or the revision of monoclonal antibody therapies to address new variant antigens.Dr. James Hayward president and CEO of Applied DNA stated The lack of NGS gene sequencing capacity in the U.S. with which to confirm specific variant identity is creating a demand for easy-to-use and cost-effective positive sample prescreening tools to supplement and strengthen the NGS capacity of participating laboratories. As the epidemiological threat changes with the arrival of new lineages or as the dominant VOC lineages evolve mutations that are naturally selected for improved viral fitness the need to sequence samples via NGS will continue to grow and put further strain on the nations finite NGS capacity. We believe the best way to efficiently allocate this important national resource is to select only valuable samples for sequencing via the use of a qPCR decision matrix powered by our SGS Panel and Assay Kit. We believe that the identification of known VOCs and new variants from other phylogenetic paths is essential to containing the spread of COVID-19 even and especially in the face of a successful vaccination campaign.About the Linea COVID-19 Assay Kit and the Linea COVID-19 Selective Genomic Surveillance SGS Mutation PanelThe Linea COVID-19 Assay Kit is authorized by FDA EUA for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens including anterior nasal swabs self-collected at a healthcare location or collected by a healthcare worker and nasopharyngeal and oropharyngeal swabs mid-turbinate nasal swabs nasopharyngeal washesaspirates or nasal aspirates and bronchoalveolar lavage BAL specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by their healthcare provider. The scope of the Linea COVID-19 Assay Kit EUA as amended is expressly limited to use consistent with the Instructions for Use by authorized laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 CLIA to perform high complexity tests. The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection andor diagnosis of COVID-19 is terminated or until the EUAs prior termination or revocation. The diagnostic kit has not been FDA cleared or approved and the EUAs limited authorization is only for the detection of nucleic acid from SARS-CoV-2 not for any other viruses or pathogens.The Linea COVID-19 Selective Genomic Surveillance SGS Mutation Panel the SGS Panel is for Research Use Only RUO and shall not be used for clinical diagnostic purposes. The SGS Panel has not been approved or authorized to diagnose ameliorate andor detect any disease by any U.S. or international regulatory authority. In addition all NGS services to be offered by the Company will be for Research Use Only RUO.
🔍 Key Information
📄
Tender Reference No.
460863023
📅
Publication Date
13 Mar 2021
🌐
Sector
Healthcare Equipment and Services
📝
Notice Type
News
📍
Location
United states
📁
Documents & Downloads
No documents found
🏷️ CPV
No CPV found
Need help with this bid?
Our bid experts can help you find, evaluate & win more tenders.